TCR1020-CD8 T cells therapy(University Of Pennsylvania)

N/A

Report date: 2025/06/12 20:00:09

Base Information

Drug NameTCR1020-CD8 T cells therapy(University Of Pennsylvania)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > TCR therapy
Mechanisms of ActionT lymphocyte replacements
TargetsUpdating
Therapy Area/IndicationsPancreatic NeoplasmsColorectal Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesUniversity Of Pennsylvania
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesUniversity Of Pennsylvania
Active IndicationsN/A
Inactive IndicationsPancreatic NeoplasmsColorectal Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A